Clinical Trial Update: Risedronate 75mg Dosed on 2 Consecutive Days Monthly in the Treatment of Osteoporosis in Postmenopausal Women [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating risedronate 75 mg given on two consecutive days each month for postmenopausal osteoporosis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postmenopausal Osteoporosis

Drugs mentioned

• Risedronate 75mg (risedronate)

Snippet

Sponsor: Sanofi | Conditions: Osteoporosis Postmenopausal | Phase 3 | Status: COMPLETED